|
1
|
Dimaras H, Kimani K, Dimba EA, Gronsdahl
P, White A, Chan HS and Gallie BL: Retinoblastoma. Lancet.
379:1436–1446. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Broaddus E, Topham A and Singh AD:
Incidence of retinoblastoma in the USA: 1975–2004. Br J Ophthalmol.
93:21–23. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Abramson DH, Beaverson K, Sangani P, Vora
RA, Lee TC, Hochberg HM, Kirszrot J and Ranjithan M: Screening for
retinoblastoma: Presenting signs as prognosticators of patient and
ocular survival. Pediatrics. 112:1248–1255. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Beta M, Venkatesan N, Vasudevan M,
Vetrivel U, Khetan V and Krishnakumar S: Identification and
insilico analysis of retinoblastoma serum microRNA profile and gene
targets towards prediction of novel serum biomarkers. Bioinform
Biol Insights. 7:21–34. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wang J, Wang X, Wu G, Hou D and Hu Q:
MiR-365b-3p, down-regulated in retinoblastoma, regulates cell cycle
progression and apoptosis of human retinoblastoma cells by
targeting PAX6. FEBS Lett. 587:1779–1786. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jabbour P, Chalouhi N, Tjoumakaris S,
Gonzalez LF, Dumont AS, Chitale R, Rosenwasser R, Bianciotto CG and
Shields C: Pearls and pitfalls of intraarterial chemotherapy for
retinoblastoma. J Neurosurg Pediatr. 10:175–181. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kaliki S, Shields CL, Rojanaporn D,
Al-Dahmash S, McLaughlin JP, Shields JA and Eagle RC Jr: High-risk
retinoblastoma based on international classification of
retinoblastoma: Analysis of 519 enucleated eyes. Ophthalmology.
120:997–1003. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Canturk S, Qaddoumi I, Khetan V, Ma Z,
Furmanchuk A, Antoneli CB, Sultan I, Kebudi R, Sharma T,
Rodriguez-Galindo C, et al: Survival of retinoblastoma in
less-developed countries impact of socioeconomic and health-related
indicators. Br J Ophthalmol. 94:1432–1436. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lin S and Gregory RI: MicroRNA biogenesis
pathways in cancer. Nat Rev Cancer. 15:321–333. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bagnyukova TV, Pogribny IP and Chekhun VF:
MicroRNAs in normal and cancer cells: A new class of gene
expression regulators. Exp Oncol. 28:263–269. 2006.PubMed/NCBI
|
|
11
|
D'Angelo B, Benedetti E, Cimini A and
Giordano A: MicroRNAs: A puzzling tool in cancer diagnostics and
therapy. Anticancer Res. 36:5571–5575. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kloosterman WP and Plasterk RH: The
diverse functions of microRNAs in animal development and disease.
Dev Cell. 11:441–450. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wu L, Chen Z and Xing Y: MiR-506-3p
inhibits cell proliferation, induces cell cycle arrest and
apoptosis in retinoblastoma by directly targeting NEK6. Cell Biol
Int. 2018. View Article : Google Scholar
|
|
16
|
Jin RH, Yu DJ and Zhong M: MiR-1269a acts
as an onco-miRNA in non-small cell lung cancer via down-regulating
SOX6. Eur Rev Med Pharmacol Sci. 22:4888–4897. 2018.PubMed/NCBI
|
|
17
|
Liu F, Hu H, Zhao J, Zhang Z, Ai X, Tang L
and Xie L: miR-124-3p acts as a potential marker and suppresses
tumor growth in gastric cancer. Biomed Rep. 9:147–155.
2018.PubMed/NCBI
|
|
18
|
Huang Y, Yu S, Cao S, Yin Y, Hong S, Guan
H, Li Y and Xiao H: MicroRNA-222 promotes invasion and metastasis
of papillary thyroid cancer through targeting protein phosphatase 2
regulatory subunit B alpha expression. Thyroid. 28:1162–1173. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li J and You X: MicroRNA-758 inhibits
malignant progression of retinoblastoma by directly targeting PAX6.
Oncol Rep. 40:1777–1786. 2018.PubMed/NCBI
|
|
20
|
Yang L, Wei N, Wang L, Wang X and Liu QH:
miR-498 promotes cell proliferation and inhibits cell apoptosis in
retinoblastoma by directly targeting CCPG1. Childs Nerv Syst.
34:417–422. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu L, Qu W and Zhong Z: Down-regulation
of miR-503 expression predicate advanced mythological features and
poor prognosis in patients with NSCLC. Int J Clin Exp Pathol.
8:5609–5613. 2015.PubMed/NCBI
|
|
22
|
Zhou B, Ma R, Si W, Li S, Xu Y, Tu X and
Wang Q: MicroRNA-503 targets FGF2 and VEGFA and inhibits tumor
angiogenesis and growth. Cancer Lett. 333:159–169. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xu YY, Wu HJ, Ma HD, Xu LP, Huo Y and Yin
LR: MicroRNA-503 suppresses proliferation and cell-cycle
progression of endometrioid endometrial cancer by negatively
regulating cyclin D1. FEBS J. 280:3768–3779. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yin ZL, Wang YL, Ge SF, Guo TT, Wang L,
Zheng XM and Liu J: Reduced expression of miR-503 is associated
with poor prognosis in cervical cancer. Eur Rev Med Pharmacol Sci.
19:4081–4085. 2015.PubMed/NCBI
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Su Z, Tian H, Song HQ, Zhang R, Deng AM
and Liu HW: PTPN12 inhibits oral squamous epithelial carcinoma cell
proliferation and invasion and can be used as a prognostic marker.
Med Oncol. 30:6182013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Villa-Moruzzi E: PTPN12 controls PTEN and
the AKT signalling to FAK and HER2 in migrating ovarian cancer
cells. Mol Cell Biochem. 375:151–157. 2013.PubMed/NCBI
|
|
28
|
Lin Q, Wang H, Lin X, Zhang W, Huang S and
Zheng Y: PTPN12 affects nasopharyngeal carcinoma cell proliferation
and migration through regulating EGFR. Cancer Biother Radiopharm.
33:60–64. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang YY, Liu H, Mao XY, Jin F, Ma B, Jiang
JY and Cao Y: Identifying the role of PTPN12 expression in
predicting the efficacy of capecitabine to neoadjuvant chemotherapy
in breast cancer treatment. Eur Rev Med Pharmacol Sci.
20:3400–3409. 2016.PubMed/NCBI
|
|
30
|
Zhang J, He J and Zhang L: The
down-regulation of microRNA-137 contributes to the up-regulation of
retinoblastoma cell proliferation and invasion by regulating
COX-2/PGE2 signaling. Biomed Pharmacother. 106:35–42. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wu S, Ai N, Liu Q and Zhang J: MicroRNA448
inhibits the progression of retinoblastoma by directly targeting
ROCK1 and regulating PI3K/AKT signalling pathway. Oncol Rep.
39:2402–2412. 2018.PubMed/NCBI
|
|
32
|
Golabchi K, Soleimani-Jelodar R, Aghadoost
N, Momeni F, Moridikia A, Nahand JS, Masoudifar A, Razmjoo H and
Mirzaei H: MicroRNAs in retinoblastoma: Potential diagnostic and
therapeutic biomarkers. J Cell Physiol. 233:3016–3023. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chong Y, Zhang J, Guo X, Li G, Zhang S, Li
C, Jiao Z and Shao M: MicroRNA-503 acts as a tumor suppressor in
osteosarcoma by targeting L1CAM. PLoS One. 9:e1145852014.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Peng Y, Liu YM, Li LC, Wang LL and Wu XL:
microRNA-503 inhibits gastric cancer cell growth and
epithelial-to-mesenchymal transition. Oncol Lett. 7:1233–1238.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wang T, Ge G, Ding Y, Zhou X, Huang Z, Zhu
W, Shu Y and Liu P: MiR-503 regulates cisplatin resistance of human
gastric cancer cell lines by targeting IGF1R and BCL2. Chin Med J
(Engl). 127:2357–2362. 2014.PubMed/NCBI
|
|
36
|
Long J, Ou C, Xia H, Zhu Y and Liu D:
MiR-503 inhibited cell proliferation of human breast cancer cells
by suppressing CCND1 expression. Tumour Biol. 36:8697–8702. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Guo J, Liu X and Wang M: miR-503
suppresses tumor cell proliferation and metastasis by directly
targeting RNF31 in prostate cancer. Biochem Biophys Res Commun.
464:1302–1308. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chi Y, Ding F, Zhang W and Du L:
microRNA-503 suppresses the migration, proliferation and colony
formation of prostate cancer cells by targeting tumor protein D52
like 2. Exp Ther Med. 15:473–478. 2018.PubMed/NCBI
|
|
39
|
Noguchi T, Toiyama Y, Kitajima T, Imaoka
H, Hiro J, Saigusa S, Tanaka K, Inoue Y, Mohri Y, Toden S and
Kusunoki M: miRNA-503 promotes tumor progression and is associated
with early recurrence and poor prognosis in human colorectal
cancer. Oncology. 90:221–231. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Li L, Zhang X, Yi Z, Liang X, Yin W and Li
S: MiR-503 promotes the migration and invasion of colorectal cancer
cells by regulating PDCD4. J BUON. 23:579–586. 2018.PubMed/NCBI
|
|
41
|
Ide S, Toiyama Y, Shimura T, Kawamura M,
Yasuda H, Saigusa S, Ohi M, Tanaka K, Mohri Y and Kusunoki M:
MicroRNA-503 promotes tumor progression and acts as a novel
biomarker for prognosis in oesophageal cancer. Anticancer Res.
35:1447–1451. 2015.PubMed/NCBI
|
|
42
|
Xiao F, Zhang W, Chen L, Chen F, Xie H,
Xing C, Yu X, Ding S, Chen K, Guo H, et al: MicroRNA-503 inhibits
the G1/S transition by downregulating cyclin D3 and E2F3 in
hepatocellular carcinoma. J Transl Med. 11:1952013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Li B, Liu L, Li X and Wu L: miR-503
suppresses metastasis of hepatocellular carcinoma cell by targeting
PRMT1. Biochem Biophys Res Commun. 464:982–987. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Xiao Y, Tian Q, He J, Huang M, Yang C and
Gong L: MiR-503 inhibits hepatocellular carcinoma cell growth via
inhibition of insulin-like growth factor 1 receptor. Onco Targets
Ther. 9:3535–3544. 2016.PubMed/NCBI
|
|
45
|
Yang X, Zang J, Pan X, Yin J, Xiang Q, Yu
J, Gan R and Lei X: miR-503 inhibits proliferation making human
hepatocellular carcinoma cells susceptible to 5-fluorouracil by
targeting EIF4E. Oncol Rep. 37:563–570. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Yang Y, Liu L, Zhang Y, Guan H, Wu J, Zhu
X, Yuan J and Li M: MiR-503 targets PI3K p85 and IKK-β and
suppresses progression of non-small cell lung cancer. Int J Cancer.
135:1531–1542. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Qiu T, Zhou L, Wang T, Xu J, Wang J, Chen
W, Zhou X, Huang Z, Zhu W, Shu Y and Liu P: miR-503 regulates the
resistance of non-small cell lung cancer cells to cisplatin by
targeting Bcl-2. Int J Mol Med. 32:593–598. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Tonks NK: Protein tyrosine phosphatases:
From genes, to function, to disease. Nat Rev Mol Cell Biol.
7:833–846. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Liang T, Li L, Cheng Y, Ren C and Zhang G:
MicroRNA-194 promotes the growth, migration and invasion of ovarian
carcinoma cells by targeting protein tyrosine phosphatase
nonreceptor type 12. Onco Targets Ther. 9:4307–4315. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Li J, Davidson D, Martins Souza C, Zhong
MC, Wu N, Park M, Muller WJ and Veillette A: Loss of PTPN12
stimulates progression of ErbB2-dependent breast cancer by
enhancing cell survival, migration and epithelial-to-mesenchymal
transition. Mol Cell Biol. 35:4069–4082. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Luo RZ, Cai PQ, Li M, Fu J, Zhang ZY, Chen
JW, Cao Y, Yun JP, Xie D and Cai MY: Decreased expression of PTPN12
correlates with tumor recurrence and poor survival of patients with
hepatocellular carcinoma. PLoS One. 9:e855922014. View Article : Google Scholar : PubMed/NCBI
|
